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A B S T R A C T
Alzheimer's disease (AD) is characterised by a dynamic process of neurocognitive changes from normal cognition
to mild cognitive impairment (MCI) and progression to dementia. However, not all individuals with MCI develop
dementia. Predicting whether individuals with MCI will decline (i.e. progressive MCI) or remain stable (i.e.
stable MCI) is impeded by patient heterogeneity due to comorbidities that may lead to MCI diagnosis without
progression to AD. Despite the importance of early diagnosis of AD for prognosis and personalised interventions,
we still lack robust tools for predicting individual progression to dementia. Here, we propose a novel trajectory
modelling approach based on metric learning (Generalised Metric Learning Vector Quantization) that mines
multimodal data from MCI patients in the Alzheimer's disease Neuroimaging Initiative (ADNI) cohort to derive
individualised prognostic scores of cognitive decline due to AD. We develop an integrated biomarker generation–
using partial least squares regression– and classification methodology that extends beyond binary patient
classification into discrete subgroups (i.e. stable vs. progressive MCI), determines individual profiles from
baseline (i.e. cognitive or biological) data and predicts individual cognitive trajectories (i.e. change in memory
scores from baseline). We demonstrate that a metric learning model trained on baseline cognitive data (memory,
executive function, affective measurements) discriminates stable vs. progressive MCI individuals with high ac-
curacy (81.4%), revealing an interaction between cognitive (memory, executive functions) and affective scores
that may relate to MCI comorbidity (e.g. affective disturbance). Training the model to perform the same binary
classification on biological data (mean cortical β-amyloid burden, grey matter density, APOE 4) results in similar
prediction accuracy (81.9%). Extending beyond binary classifications, we develop and implement a trajectory
modelling approach that shows significantly better performance in predicting individualised rate of future
cognitive decline (i.e. change in memory scores from baseline), when the metric learning model is trained with
biological (r = −0.68) compared to cognitive (r = −0.4) data. Our trajectory modelling approach reveals
interpretable and interoperable markers of progression to AD and has strong potential to guide effective stra-
tification of individuals based on prognostic disease trajectories, reducing MCI patient misclassification, that is
critical for clinical practice and discovery of personalised interventions.
1. Introduction
Progression to dementia due to Alzheimer's Disease (AD) involves
multiple pathways of disease pathophysiology that impact cognition
(Jack et al., 2018, 2013; Jagust, 2018). Individuals who develop
dementia follow a trajectory from a stage of normal cognition to Mild
Cognitive Impairment (MCI) and subsequent dementia (McKhann et al.,
2011; Petersen et al., 2001; Sperling et al., 2011). Predicting early onset
of neurocognitive decline due to AD has major implications for timely
clinical management and patient outcomes. Yet, diagnosis at early
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stages of disease is impeded by heterogeneity in patient populations due
to comorbidities (e.g. affective or cerebrovascular disorders) that may
lead to MCI diagnosis without further progression to AD
(Petersen, 2009). Determining disease trajectories for individuals di-
agnosed with MCI has major implications for prognosis and persona-
lised interventions.
Recent advances in machine learning allow us to develop predictive
models of neurodegenerative disease by mining multimodal datasets
that include measurements of cognition and neuropathology from large
patient cohorts (Woo et al., 2017). In line with the 2011 NIA-AA di-
agnostic framework for mild cognitive impairment or dementia stages
in AD (Albert et al., 2011; McKhann et al., 2011), most machine
learning models in AD have focused on binary classifications. For ex-
ample, machine learning models have been shown to predict with high
accuracy whether individuals diagnosed with MCI will decline (i.e.
progressive MCI; pMCI) or remain stable (i.e. stable MCI; sMCI)
(Rathore et al., 2017). Fewer models have achieved prediction of in-
dividual variability in disease progression (Tang et al., 2015; Woo et al.,
2017) focusing primarily on probabilistic estimates of time to conver-
sion to AD (Alsaedi et al., 2018; Casanova et al., 2013; Desikan et al.,
2010; Jack et al., 2010; Liu et al., 2017; Michaud et al., 2017;
Oulhaj et al., 2009; Young et al., 2014), with some models estimating
exact time to conversion (Dukart et al., 2015; Thung et al., 2018;
Vogel et al., 2018).
Despite the high prediction accuracies achieved by machine
learning algorithms, binary classification approaches are poorly con-
strained, as they are based on clinical labels rather than capturing in-
formation in longitudinal patient trajectories. As a result, individual
patients at the class boundary that differ only slightly in their profile
may be misclassified. Further, the validity and statistical power
(Li et al., 2019) of these approaches is limited by the frequency of
clinical follow-ups (i.e. the point of conversion may occur between
clinical assessments) and inter-rater reliability (i.e. clinicians may differ
in their assessment). Extending machine learning modelling to predict
measures determined by diagnostic labelling (i.e. time to conversion)
suffers from the same limitations, introducing bias and limiting the
interpretability and interoperability of machine learning algorithms
(Janssen et al., 2018). Thus, novel modelling approaches that predict
individualised trajectories of cognitive decline based on continuous
measures need to be developed to enhance clinical validity and guide
effective clinical interventions and drug discovery trials.
Here, we develop and implement a trajectory modelling approach
that extends beyond binary classification. We use machine learning
(metric learning) algorithms to stratify patients at early stages of im-
pairment (i.e. MCI) based on baseline cognitive or biological data and
determine individual prognostic trajectories based on continuous
measures of cognitive decline (i.e. change in memory scores over time).
Our trajectory modelling approach allows us to extract continuous in-
formation about progression to AD, in line with the current 2018 NIA-
AA research framework that has transitioned to defining AD as a con-
tinuum (Jack et al., 2018).
In particular, we used large-scale data from the Alzheimer's disease
Neuroimaging Initiative (ADNI) database. Cognitive data comprise
composite scores across tasks; that is, summative measures of memory
(i.e., ADNI-Mem (Crane et al., 2012)), executive function (i.e., ADNI–EF
(Gibbons et al., 2012)), and depression (Yesavage, 1988). Similar
composite measures have been shown to be effective for diagnosing
cognitive dysfunction (Ayutyanont et al., 2014; Donohue et al., 2014;
Jutten et al., 2018; 2017; Langbaum et al., 2014). In addition, we used
well-studied biomarkers of AD (Jagust, 2018; Resnick and
Sojkova, 2011); that is, grey matter density derived from structural MRI
scans, β-amyloid burden from PET scans and APOE 4 status.
We adopted a metric learning framework (Generalised Metric
Learning Vector Quantization, GMLVQ) and extended our approach
beyond binary classification (i.e. sMCI vs. pMCI) to modelling of con-
tinuous measurements (i.e. change in ADNI-Mem scores) (Figure 1). In
particular, we first tested a low-parameter, interpretable model on a
binary classification task (sMCI vs. pMCI) and interrogated the key
cognitive predictors that separate sMCI vs. pMCI individuals. This
modelling revealed ADNI-Mem as the most discriminative cognitive
feature for classifying sMCI vs. pMCI, in line with previous work
showing that ADNI-Mem captures memory performance in amnestic
MCI populations (Crane et al., 2012). We then developed a novel fea-
ture selection and construction method based on partial least squares
regression (PLSr) to generate an interpretable and interoperable dis-
ease-specific biomarker (i.e. grey matter atrophy due to AD) that pre-
dicts memory deficits as measured by ADNI-Mem, discriminates sMCI
vs. pMCI individuals and relates to individual tau burden, as measured
by flortaucipir PET in an independent sample. We then trained our
metric learning model on biological data– including the PLS-derived
grey-matter feature, mean cortical β-amyloid burden, and APOE 4– and
compared the classification accuracy across models trained with either
cognitive or biological data.
To extend our modelling approach beyond binary classification (i.e.
sMCI vs. pMCI), we derived a scalar projection (i.e. distance of each
individual from the sMCI prototype) based on the metric learning
model that allows us to determine a continuous metric of disease pro-
gression. We demonstrate that this metric relates to rate of future
cognitive decline (i.e. change in ADNI-Mem scores following baseline),
providing evidence that our methodology delivers a continuous prog-
nostic score of individual cognitive decline due to AD. Further, our
trajectory modelling approach determines predictive cognitive markers
of individual variability in AD progression; yet, predicting disease tra-
jectories improves when including non-invasively measured and inter-
pretable biomarkers (i.e. grey matter density and/or APOE 4).
2. Methods and materials
2.1. ADNI participants
Data were obtained from the Alzheimer's disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu). ADNI was launched in
2003 as a public-private partnership, led by Principal Investigator
Michael W. Weiner, MD. A major goal of ADNI has been to examine
biomarkers including serial magnetic resonance imaging (MRI), and
positron emission tomography (PET), with clinical and neuropsycho-
logical assessment to predict outcomes in mild cognitive impairment
(MCI) and early Alzheimer's disease (AD). Data samples are defined as:
(1) Development data samples used for model formulation and within-
sample validation, (2) independent validation data samples used for
out-of-sample validation. Below we provide details for each data
sample:
2.1.1. Development sample
Data from 589 individuals (baseline diagnoses: Normal =317,
MCI=272) from ADNI-GO and ADNI-2 were used for model formula-
tion and within-sample validation. For these individuals the baseline
assessments (MRI and cognitive) were those closest to the time of the
first florbetapir (FBP) PET scan. All individuals had baseline cognitive
measurements, 3T structural MRI, FBP-PET scan for measuring β-
amyloid, and APOE genotyping. All individuals were included in this
cross sectional sample independent of their future diagnosis (i.e. whe-
ther following baseline an individual's diagnosis changed from cogni-
tively normal to MCI/AD).
2.1.2. Development sample I
253 MCI individuals (of a total of 272) have at least 3 longitudinal
cognitive testing sessions. Data from these individuals were used for
model formulation and within-sample validation for the continuous
longitudinal outcome prediction models.
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2.1.3. Development sample II
167 MCI individuals (of the 253 MCI individuals in Development
Sample I) have 3 years of clinical diagnostic assessments. Data from
these individuals were used as dichotomous outcomes (stable vs. pro-
gressive MCI) for longitudinal predictions.
2.1.4. Cross-modal associations validation sample
To out-of-sample-validate the model that predicted cross-modality
associations (e.g. predict ADNI-Mem scores from grey-matter), we drew
an independent validation sample comprised of 446 individuals
(Normal=263, MCI=172, AD=11) from ADNI-3. These individuals
have a 3T structural MRI, and cognitive measures in addition to a
flortaucipir (FTP) PET scan for measuring cortical tau.
2.1.5. Cross-modal associations validation sample I
We selected 219 individuals from the Cross-modal associations va-
lidation sample (Normal=122, MCI=89, AD=8), excluding in-
dividuals with an FTP-PET scan who were part of the Development
Sample. Individuals in the Cross-modal associations validation sample I
were newly recruited into ADNI-3, that is they had not been enroled in
ADNI-GO or ADNI-2 prior to enroling in ADNI-3. This independent
sample was used to validate cross-modal associations of grey matter and
ADNI-Mem scores. All data from the Cross-modal associations valida-
tion sample were taken from assessments closest in time to the FTP-PET
scan.
2.1.6. Longitudinal prediction validation sample
To out-of-sample-validate the model that generated longitudinal
predictions, we drew an independent validation sample comprising 126
MCI individuals (ADNI-GO, ADNI-2). These individuals have baseline
cognitive, 3T structural MRI, FBP-PET measurements and APOE 4
genotyping. As for the data used for model formulation, baseline was
defined as the assessment closest in time to an individual's first FBP-PET
scan acquired in ADNI. These individuals also have at least 3 long-
itudinal cognitive testing sessions that were used to validate the out-
come measures for longitudinal predictions. See Supplementary Table
S1 for sample demographics.
3. Brain imaging data
3.1. MRI acquisition
Structural MRIs were acquired at ADNI-GO, ADNI-2 and ADNI-3
sites equipped with 3 T MRI scanners using a 3D MP-RAGE or IR-SPGR
T1-weighted sequences, as described online (http://adni.loni.usc.edu/
methods/documents/mri-protocols).
3.2. PET acquisition
PET imaging was performed at each ADNI site according to stan-
dardised protocols. The FBP-PET protocol entailed the injection of 10
mCi with acquisition of 20 min of emission data at 50–70 min post
injection. The FTP-PET protocol entailed the injection of 10 mCi of
tracer followed by acquisition of 30 min of emission data from
75–105 min post injection.
3.3. Image analysis: FTP (Flortaucipir PET) Tau
FTP data were realigned, and the mean of all frames was used to
coregister FTP to each participant's MRI acquired closest to the time of
the FTP-PET. FTP standardised uptake value ratio (SUVR) images were
normalised to inferior cerebellar grey matter (Baker et al., 2017). MR
images were segmented and parcellated using Freesurfer (V5.3) and
regions of interest were used to extract cerebellar-normalised regional
SUVR data. SUVR data was summarised for three Braak staging regions
12 (medial temporal), 34 (inferolateral temporal) and 56 (extra-tem-
poral neocortical) by averaging uptake across individual Freesurfer
region of interests (ROIs) comprising each Braak region (Maass et al.,
2017). Finally, we assigned individuals as tau positive for each Braak
stage if their SUVR value was greater than the 90th percentile of
amyloid-negative, cognitively normal individuals.
3.4. Image analysis: FBP (Florbetapir PET) beta amyloid
FBP data were realigned, and the mean of all frames was used to co-
register FBP data to each participant's structural MRI. Cortical SUVRs
were generated by averaging FBP retention in a standard group of ROIs
(lateral and medial frontal, anterior and posterior cingulate, lateral
parietal, and lateral temporal cortical grey matter) and dividing by the
average uptake from a composite reference region (including the whole
cerebellum, pons/brainstem, and eroded subcortical white matter re-
gions) to create an index of global cortical FBP burden for each subject
(Landau et al., 2015).
3.5. Image analysis voxel based morphometry (VBM)
Structural scans were segmented into grey matter, white matter and
CSF (Cerebrospinal Fluid). The DARTEL toolbox (Ashburner, 2007) was
then used to generate a study specific template to which all scans were
normalised. Following this, individual grey matter segmentation vo-
lumes were normalised to MNI space without modulation. The un-
modulated values for each voxel represent grey matter density at the
voxel location. We chose to use the unmodulated grey matter data as it
has been shown that there is a marked decrease in sensitivity to de-
tecting abnormal regions within grey matter when the data is modu-
lated (Radua et al., 2014) (for analysis with modulated data, see Sup-
plementary Figure S4b, Supplementary Table S2b).
All images were then smoothed using a 3 mm3 isotropic kernel and
resliced to MNI resolution 1.5 × 1.5 × 1.5 mm voxel size. We used a
small kernel size, as topographically complex and relatively small
cortical regions are likely to be affected in AD (i.e. structures within the
medial temporal cortex; e.g. hippocampus, entorhinal cortex). It has
Fig. 1. Modelling framework.
a. PLSr-RFE was used to generate the PLS derived grey matter score and out-of-sample-tests for cross modal associations. Using the Development Sample a voxel
weights matrix is learned and validated using k-fold cross-validation to predict ADNI-Mem. Using this voxel weights matrix, we generated the PLS derived grey
matter score for the Cross-modal associations validation sample to test the cross modal association between the PLS derived grey matter score and cortical tau
(flortaucipir, or FTP-PET). We used the Cross-modal Associations validation sample I to out-of-sample validate the relationship between the PLS derived grey matter
score and ADNI-Mem. The voxel weights matrix generated is then used to derive the PLS derived grey matter feature for the data used in panels b and c. b. GMLVQ
binary classification was used to discriminate between sMCI and pMCI based on biological or cognitive data. Using Development sample II, GMLVQ binary classifiers
were trained and validated using k-fold cross-validation to predict progression to dementia from MCI (sMCI vs pMCI). (c) GMLVQ-Scalar Projection was used to
generate the cognitive and biological scalar projections and out-of-sample validate the relationship of the scalar projections with rate of future cognitive decline.
Using Development Sample I, cognitive and biological scalar projections were generated and correlated to rate of change in future ADNI-Mem scores. This re-
lationship was validated using random resampling. Further, the relationship of the scalar projection and rate of future cognitive decline was validated with rate of
change of future MMSE using Development Sample I. The prototype position and metric tensor learned from the GMLVQ-Scalar projection using Development Sample
I were then used to derive the cognitive and biological scalar projections for the longitudinal prediction validation sample to test the out-of-sample relationship
between the scalar projection and rate of future cognitive decline.
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been suggested that smoothing beyond a 3 mm kernel may artificially
link small but discrete clusters of voxels, reducing topographic sensi-
tivity (Radua et al., 2014). Further, our analysis applies a spatial de-
composition across voxels. By sampling the spatial covariance structure
across voxels, disease related non-parametric variations at the voxel
level (that are mitigated using larger smoothing kernels in parametric
statistical tests across participants) are preserved when using smaller
kernel sizes, improving the efficacy of the analysis method. All struc-
tural MRI pre-processing was performed using Statistical Parametric
Mapping 12 (http://www.fil.ion.ucl.ac.uk/spm/).
3.6. Cognitive scores
We used three baseline cognitive scores as predictors for long-
itudinal models: a) composite scores of memory function (ADNI-Mem)
derived from the Rey Auditory Verbal Learning, AD Assessment
Schedule-Cognition, Mini-Mental State Examination and Logical
Memory tests (Crane et al., 2012). b) composite scores of executive
function (ADNI-EF) derived from the WAIS-R Digit Symbol Substitu-
tion, Digit Span Backwards, Trails A and B, Category Fluency and Clock
Drawing tests (Gibbons et al., 2012). c) the sum of all elements from the
geriatric depression scale (GDS) (Yesavage, 1988). As individuals are
excluded from ADNI with a GDS >5 we investigate affective dis-
turbance at subthreshold levels of clinical depression.
3.7. Generalised Metric Learning Vector Quantization (GMLVQ)
We used the Generalised Metric Learning Vector Quantization
(GMLVQ) framework (Schneider et al., 2009) to generate and test
binary classification models (Supplementary Methods GMLVQ) that
classify sMCI vs. pMCI individuals (Development Sample II). In-
dividuals were characterised as sMCI if they repeatedly received an MCI
diagnosis for more than three years of clinical observation. Individuals
who progressed from MCI to AD within a window of 3 years of clinical
observation were characterised as pMCI. Individuals who progressed
from MCI to AD after 3 years were excluded from the Development
Sample II.
GMLVQ belongs to the class of classifiers referred to as Learning
Vector Quantization (LVQ). These classifiers operate in a supervised
manner to iteratively modify class-specific prototypes and learn
boundaries between classes. For each training example, the closest
prototype of each class is determined, these prototypes are then up-
dated so that the prototype defining the same class is moved towards
the training example and other prototype(s) representing different class
(es) are moved further away. The Generalised Metric LVQ (GMLVQ)
extends the LVQ utilising a full metric-tensor for a more robust distance
measure. By applying the metric-tensor, specific feature scaling can
occur while also accounting for different feature scales and pairwise
task-conditional dependencies in the input space. Interrogating the di-
agonal terms allow us to determine the key univariate predictors for
separating sMCI vs. pMCI patients. Further, interrogating the off diag-
onal terms of the metric tensor allow us to investigate the multivariate
predictors that contribute to this classification task.
3.8. GMLVQ cognitive model
We used the (GMLVQ) framework to generate and test binary
classification models that classify sMCI vs. pMCI individuals
(Development Sample II) based on cognitive measures (GDS, ADNI-
Mem and ADNI-EF).
3.9. Partial least squares regression with recursive feature elimination
(PLSr-RFE)
We implemented Partial Least Squares Regression with Recursive
Feature Elimination (PLSr-RFE) (Supplementary Methods PLS) to
generate a grey matter density feature based on data from the
Development sample (normal and MCI individuals). All 3T structural
MRI scans in the Development sample were collected using a 3D MP-
RAGE T1-weighted sequence. In particular, we used grey matter density
measured by structural MRI as a predictor variable to determine mul-
tivariate relationships between grey matter voxels that best predict
ADNI-Mem, as our GMLVQ modelling showed ADNI-Mem to be the
most heavily weighted cognitive feature for the sMCI vs. pMCI classi-
fication. (Supplementary Methods PLS). We performed feature set con-
struction using PLSr and feature reduction using recursive feature
elimination. PLSr determines multivariate relationships between pre-
dictor variables to best describe response variables. In particular, PLSr
applies a decomposition on a set of predictors to create orthogonal la-
tent variables that show the maximum covariance with the response
variables (Krishnan et al., 2011; McIntosh and Lobaugh, 2004). In our
study, we used PLSr to generate a set of latent predictor variables from
structural MRI data, where a) the number of features (i.e. grey matter
voxels) is far greater than the number of observations (e.g. number of
voxels >300,000, number of observations <1000), b) there is high
degree of multi-collinearity between voxels. PLSr reduces redundant
information and maximises the amount of variance that the latent
variables predict in the response variable. Further, we performed re-
cursive feature elimination by iteratively removing voxels that have
weak predictive value. To determine the optimal number of grey matter
voxels to be retained, we used a 5 fold nested cross validation and an
early stopping paradigm (Supplementary Methods, PLSr Recursive Fea-
ture Elimination).
3.10. GMLVQ biological model
We followed the same methodology as for the GMLVQ Cognitive
model (Development Sample II) to test the GMLVQ model on biological
data. That is, we generated and tested binary classification models
based on metric learning that discriminate between the same sMCI vs.
pMCI individuals based on biological data (PLS derived grey matter
score, β-amyloid and APOE 4) (Supplementary Methods GMLVQ, Figure
S1). Note that this sample includes 3 pMCI individuals who were β-
amyloid negative (i.e. SUVR<1.11) at baseline. We did not restrict our
measure of β-amyloid to a binary value but rather used continuous
SUVR values to avoid model bias near the ADNI threshold for amyloid
positivity.
3.11. GMLVQ – scalar projection
We next generated a continuous prediction using either baseline
cognitive data (GDS, ADNI-Mem, ADNI-EF) or baseline biological data
(PLS Derived Grey matter score, β-amyloid, APOE 4) for MCI in-
dividuals (Development sample I). The GMLVQ- Scalar Projection
method extends the GMLVQ framework to extract specific distance
information from the sample vector xi and the learnt prototypes
w(stable,progressive). Specifically, we determine the distance in the learnt
space (i.e. after applying the learnt metric tensor) between an in-
dividual with sample vector xi and the learnt prototype wstable along the
vector separating wstable and wprogressive (Supplementary Methods GMLVQ
– Scalar Projection, Figure S2).
A value of 1 indicates that a sample vector is incident to the pMCI
prototype whereas a value of 0 indicates that a sample vector is incident
to the sMCI prototype, and a value of 0.5 is the decision boundary se-
parating the two classes within the binary classification framework. The
scalar projection has a large positive value for pMCI individuals and
zero or negative value for sMCI individuals (Supplementary Figure S3).
3.12. Relating the scalar projection to individual rates of future cognitive
decline
We used the GMLVQ-Scalar projection method for 253 MCI
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individuals (Development Sample I) to generate a cognitive scalar
projection from baseline cognitive variables (GDS, ADNI-Mem, ADNI-
EF), and a biological scalar projection from baseline biological variables
(PLS Derived Grey matter score, β-amyloid, APOE 4). To test whether
individual scalar projections relate to individual rates of future cogni-
tive decline, we correlated (Pearson's correlation) the scalar projection
(generated using baseline predictors) with the rate of future change in
ADNI-Mem scores. We computed the rate of future cognitive change by
fitting a linear model to the ADNI-Mem scores across multiple mea-
surements (Development Sample I: mean=5.7, std=1 time points;
mean=4, std=1.7 years, Longitudinal prediction validation sample:
mean=5, std=1.7 time points; mean=4.4, std=1.5 years). The slope
of the linear model represents the rate of change in ADNI-Mem score.
Individual scores higher than 2 standard deviations from the sMCI
mean score or less than 2 standard deviations from the pMCI mean
score were determined as outliers and excluded from further analysis.
4. Statistical validation
4.1. Within-sample validation
To test within-sample generalisability for the GMLVQ (Development
Sample II) and PLSr-RFE (Development Sample) models we use k-fold
cross validation. Within each cross fold we select hyper-parameters
using nested cross-validation. To assess model generalisation perfor-
mance, we averaged metrics (GMLVQ: Accuracy, Macro Averaged Error
(MAE), True Positive (TP), True Negative (TN); PLSr-RFE: Variance
Explained) from the test set across all cross folds. Within-sample gen-
eralisation for the GMLVQ-scalar projection framework (Development
Sample I) was assessed using random resampling (1000 resamplings).
We assessed within-sample generalisation based on the median of the
correlation coefficients generated from the test sets across resampling
using 95% confidence intervals.
4.2. Out-of-Sample validation
We test the out-of-sample association of the PLS derived grey matter
feature (represented by the voxel weight matrix) with memory (Cross-
modal associations validation sample I) and cortical tau (Cross-modal
associations validation sample) from the 3 selected Braak regions.
Finally, we test the out-of-sample generalisability of the GMLVQ-Scalar
Projection in predicting individual rates of future cognitive decline
(Longitudinal prediction validation sample). To ensure that our PLS-
grey matter feature is robust to different scanner sequences, we in-
cluded 3T structural MRI scans collected using either a 3D MP-RAGE or
IR-SPGR T1-weighted sequence.
4.3. Comparing correlations between samples
To test if the relationship between the GMLVQ-Scalar Projection and
rate of future cognitive decline is significantly different between
Development sample II and the Longitudinal prediction validation
samples we used Fisher's r to Z transformation. To compare if the re-
lationship of the GMLVQ-Scalar Projection and rate of future cognitive
decline is significantly different between models using biological or
cognitive data we generate a Steiger Z statistic (Steiger, 1980). See
Supplementary Methods Cross Validation Framework for a compressive
description of validation methodologies.
5. Results
5.1. Cognitive classification models for predicting sMCI vs. pMCI
We tested whether a classification model that is based on the
Generalised Metric Learning Vector Quantization (GMLVQ) framework
and trained and tested on baseline cognitive data predicts progression
from MCI to AD. In particular, we trained and tested both a linear and
non-linear classifier to discriminate between sMCI and pMCI using
cognitive data (Geriatric Depression Scale (GDS), ADNI Memory (ADNI-
Mem) and ADNI Executive Function (ADNI-EF) from a sample of 167
MCI individuals (Development Sample II). We tuned the model with 2
hyper-parameters using nested cross validation and assessed its per-
formance using 10-fold cross validation. The model successfully clas-
sified stable (sMCI; n = 113) vs. progressive (pMCI; n = 54) MCI in-
dividuals [Accuracy: 81.4%, MAE: 17.6%, TP: 84.9%, TN 79.8%]. We
obtained identical performance by increasing model complexity to a
non-linear classifier by increasing the number of prototypes per class to
two [Accuracy:81.4%, MAE:17.6%, TP:84.9%, TN 79.8%], and there-
fore selected the linear model for further analysis. Interrogating the
average metric tensor (Figure 2, SupplementaryMethods GMLVQ, Figure
S1) showed that the most predictive feature was ADNI-Mem
(mean:0.55, std:+−0.12), while ADNI-EF (mean:0.35, std:+−0.09)
and GDS (mean:0.1, std:+−0.05) had moderate and minor contribu-
tions to the classification task, respectively. These results suggest that
the baseline ADNI-Mem score is the most discriminative cognitive
feature for classifying sMCI vs. pMCI, as indicated by the diagonal terms
in the metric tensor that are scaled to sum to one. Further, learning a
metric in the input space of the classifier enables us to extend beyond
the weighting of individual input features (such as ADNI-Mem score)
and study the higher-order interplay between pairs of features with
respect to the classification task. Interrogating the off diagonal terms of
the metric tensor indicates that the interaction of GDS with ADNI-Mem
or ADNI-EF is important for classifying sMCI vs. pMCI individuals. The
positive off-diagonal terms indicate a positive interaction between the
ADNI-Mem and ADNI-EF scores that group individuals from the same
class. In contrast, the negative off diagonal terms indicate that the GDS
score has a negative interaction with the ADNI-Mem and ADNI-EF
scores and separate individuals into different classes. For example, in-
dividuals with similar baseline ADNI-Mem and ADNI-EF scores may be
classified in different groups depending on their baseline GDS score,
with higher scores likely reflecting affective disturbance and MCI co-
morbidity.
Fig. 2. Cognitive classification Model - Metric Tensor
Metric tensor for the classification model (sMCI vs pMCI) generated using
cognitive data (GDS, ADNI-Mem, ADNI-EF). The colour scale indicates the
predictive value for each cell in the metric tensor, where diagonal terms sum to
1. The diagonal terms show strong contribution of the ADNI-Mem score. The
positive off diagonals terms indicate a positive interaction between the ADNI-
Mem and ADNI-EF scores. The negative off diagonals terms indicate the ne-
gative interaction of the GDS score with the ADNI-Mem and ANDNI-EF scores.
See also Figure S1 for examples of GMLVQ and possible interpretations (For
interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.).
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5.2. Composite grey matter score for predicting cross-modality associations
We next determined the spatial distribution and weight of grey
matter voxels that are associated with memory loss in AD. We used
PLSr-RFE on data from cognitively normal and MCI individuals
(Development Sample), to derive latent features based on whole-brain
grey matter that predict baseline ADNI-Mem, as this was shown to be
the most discriminative cognitive feature for classifying sMCI vs. pMCI
individuals. We determined the optimal number of grey matter voxels
and PLS dimensions to retain, using nested cross validation within each
of 5 cross folds. We observed that the predictive voxels aggregated
within the medial temporal cortex (Figure 3a, Supplementary Table S3)
and that a single PLS dimension explained comparable variance in the
ADNI Mem score in both training [r2(587) = 0.1855, P < 0.0001] and
test [r2(587) = 0.1756, P < 0.0001] sets (Supplementary Figure S4a,
Supplementary Table S2a). No other PLS components were retained
following cross validation.
Next, we derived a PLS derived grey matter score for a validation
sample that did not include individuals that were used in the model
development (Cross-modal associations validation sample I). This value
represents the weighted linear sum of grey matter voxels that best de-
scribed the ADNI-Mem score in the Development sample. We showed
that this score accounts significantly for variance in ADNI-Mem for the
Cross-modal associations validation sample I (n = 219) that was not
previously used in the PLSr-RFE feature generation ([r2(217) = 0.33, P
< 0.0001]). This relationship remained significant when we controlled
for (Age; r2(216) = 16%, P<0.0001, Gender; r2(216) = 24%
P<0.0001, or Education; r2(216) =37% P<0.0001). It is likely that the
higher variance explained by the PLS derived grey matter score for the
validation sample I relative to the development sample is due to the
significantly higher degree of atrophy (lower PLS grey matter score) in
the validation sample I (Wilcoxon Signed Rank; z=−3.42, p<0.0001).
That is, a greater amount of variance in ADNI-Mem is likely explained
by the greater amount of AD related atrophy in the validation sample.
Further, we observed significant differences (independent sample t-
tests) in the PLS derived grey matter score between three sub-groups
(cognitively normal, sMCI and pMCI) within the Development sample
used in the PLSr-RFE analysis. In particular, the cognitively normal
group showed significantly higher scores than the pMCI group (t(170)
=9.13, P<0.0001, Cohens D= 1.5) and the sMCI showed significantly
higher score than pMCI group (t(165)=5.7, P<0.0001, Cohens
D = 0.94). However, when comparing cognitively normal vs. sMCI
individuals we observed only a small effect [t(230)=3.7, P = 0.00072
(FWE Corrected), Cohens D = 0.48] (Figure 3b). Taken together these
results suggest that the PLS derived grey matter score captures variance
that relates to memory dysfunction (i.e. poor ADNI-Mem scores) due to
AD.
We next compared the variance explained in ADNI-Mem by the PLS
derived grey matter score to the variance explained by the average grey
matter density in medial temporal regions (i.e. amygdala, hippo-
campus) known to be related to ADNI-Mem (Nho et al., 2012). For each
test set within the nested cross-validation framework, we extracted
mean grey matter density from regions in the amygdala and hippo-
campus, as defined using the Brainnetome atlas (Fan et al., 2016). We
then compared the variance explained in ADNI-Mem for these a-priori
selected regions with the variance explained by the PLS derived grey
matter feature. We observed that the PLS derived grey matter score
explained significantly more variance in the ADNI-Mem score than the
mean grey matter density from a-priori selected regions in the medial
temporal cortex (t(24)=5.6, Cohens D = 1.12, P<0.0001) (Supple-
mentary Table S4). This finding suggests that the multivariate re-
lationship between grey matter voxels captured by the PLS accounts for
higher variability in individual ADNI-Mem scores than the average grey
matter density in brain regions defined by coarser parcellations.
Finally, we tested whether the PLS derived grey matter score differs
across individuals that vary in cortical tau pathology, as measured by
FTP-PET (Table 1). Comparing individuals from an independent sample
(Cross-modal associations validation sample) with tau positive vs. tau
negative scores (independent samples t-test) showed the strongest effect
within Braak stage 12 [t(444)=9.6, P<0.0001 Cohens D = 1.9]. Fur-
ther, the PLS derived grey matter score correlated (Pearson's correla-
tion) significantly with cortical tau burden across all individuals, with
the strongest effect for Braak stage 12 [r2(444) = 0.32, P< 0.0001].
These results suggest that the PLS derived grey matter score relates to
both memory deficits and tau deposition associated with AD. These
Fig. 3. PLS modelling of ADNI-Mem
a. PLS derived voxel weights matrix. Voxel weights are derived using the
PLSr-RFE methodology. Retained voxels are overlaid on the MNI template in
neurological convention (left is left). The colour scale represents the average z-
statistic of weights per voxel across all cross folds. All retained voxels are red
indicating positive weights. Table S2 lists the anatomical regions and voxel
weights for the PLS voxel matrix. The x, y and z coordinates denote the location
of the sagittal, coronal and axial slices, respectively. b. PLS derived grey
matter scores for cognitively normal, sMCI and pMCI groups: Boxplots of
the PLS derived grey matter scores for cognitively normal, sMCI and pMCI
groups. The centre line represents the median and the edges of the boxes re-
present the 25th and 75th percentiles of each sample. The medians of two
samples are significantly different at the p<0.05 if the edge of the intervals
around each notch do not overlap. Red points denote outliers (For interpreta-
tion of the references to colour in this figure legend, the reader is referred to the
web version of this article.).
Table 1
(PLS derived grey matter score relationship with flortaucipir PET Tau) re-
lationship of the PLS grey matter score with flortaucipir Tau measures. The
table shows the threshold for tau positivity for each of the Braak stages, the
statistical differences between the grey matter scores for tau positive vs. tau
negative individuals, and the correlation of the PLS grey matter score with
flortaucipir tau across all individuals.
Braak stage Threshold Tau positive vs Tau negative GM score vs
Tau
p t Cohen d Pos/Neg r2
tau Braak 12 1.95 <0.0001 9.7 1.9 27/419 0.32
tau Braak 34 1.89 <0.0001 8.3 1.5 33/413 0.15
tau Braak 56 1.93 <0.0001 5.7 1.3 21/425 0.08
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results are consistent with previous studies showing a strong relation-
ship between memory, medial temporal lobe atrophy, and regional (or
Braak 12 stage) deposition of tau (Cho et al., 2016; Harrison et al.,
2019; Johnson et al., 2016; Knopman et al., 2019; Schöll et al., 2016).
5.3. Comparing the performance of biological vs. cognitive models
We tested whether a classification model trained and tested on
baseline biological data discriminates sMCI vs. pMCI. We developed a
biological classification model of similar complexity to the cognitive
model (i.e. linear classifier (1 prototype per class), 3 features, 2 hyper
parameters) based on the same data sample (Development Sample II,
n = 167) using as predictors: PLS derived grey matter score, β-amyloid
burden (measured by FBP-PET) and APOE 4 status (positive: presence
of 1 or 2 APOE4 alleles, negative: no APOE4 alleles). The model suc-
cessfully discriminated between sMCI vs. pMCI individuals [Accuracy:
81.9%, MAE: 18.3%, True Positive: 81.1%, True Negative 82.3%]. We
observed comparable classification performance when we increased the
complexity of the biological model to a non-linear classifier (2 proto-
types per class) [Accuracy: 80.7%, MAE: 19.2%, True Positive: 81.1%,
True Negative: 80.5%]. The metric tensor of the model (Figure 4) in-
dicates that the feature with the highest predictive value is baseline β-
amyloid burden (mean:0.48, std:+−0.16), with similar contributions
from baseline PLS derived grey matter (mean:0.28, std: +- 0.14) and
APOE4 status (mean:0.24, std: +−0.10). Further, interrogating the off
diagonal terms of the metric tensor indicated a positive interaction
between baseline β-amyloid burden and APOE 4 status; that is baseline
β-amyloid burden and APOE 4 status groups individuals from the same
class. In contrast, we observed a negative interaction between baseline
β-amyloid burden and the baseline PLS derived grey matter score; that
is, the combination of these features separates sMCI from pMCI in-
dividuals. For example, individuals with high baseline β-amyloid
burden and low baseline PLS derived grey matter score (i.e. low grey
matter density in medial temporal areas) are grouped in separate
classes (sMCI vs. pMCI) from individuals with high baseline PLS derived
grey matter score (i.e. high grey matter density) and low baseline β-
amyloid burden. Finally, we observed no significant differences (t-tests
across cross folds) in classification performance between the cognitive
and biological models (Accuracy: [t(9)=−0.13, P = 0.90], MAE: [t(9)
=0.17, P = 0.87], True Positive: [t(9)=0.54, P = 0.60], True Nega-
tive: [t(9)=−0.32, P = 0.75]), suggesting that baseline cognitive and
biological features contribute similarly to the binary classification of
sMCI vs. pMCI individuals.
5.4. Trajectory modelling: predicting individual variability in the rate of
future cognitive decline
Our analyses so far have focused on binary classifications (i.e. sMCI
vs. pMCI). However, this approach is limited, as it assumes distinct
patient classes and does not capture dynamic changes in disease pro-
gression over time. To extend beyond this binary framework, we de-
veloped a trajectory modelling approach by deriving a continuous
metric based on a GMLVQ-scalar projection (i.e. distance of each MCI
patient from the sMCI prototype) and using only baseline data. We then
confirmed that this projection relates to individual variability in the
rate of future cognitive decline. In particular, we defined the rate of
future cognitive decline as the rate of change in the ADNI-Mem scores
across measurements following baseline, where baseline is defined as
the date of the FBP-PET scan used as a predictor for deriving the
GMLVQ-scalar projection. We focussed on change in memory perfor-
mance as measured by ADNI-Mem, as a) memory decline has been
shown to occur prior to decline in other cognitive domains in sporadic
AD, b) our metric leaning model showed that ADNI-Mem was the most
discriminative cognitive feature for the sMCI vs. pMCI classification
compared to the other cognitive variables tested (GDS, ADNI-EF). We
then tested whether this prognostic metric of future cognitive decline
differs for cognitive vs. biological models. For the same sample used in
the binary classifications (Development Sample II) we observed that
scalar projections derived from either the cognitive or the biological
model account significantly for variance in the rate of future memory
decline (Figure 5) (i.e. Cognitive: [r(165) = −0.41 (95% CI: [−0.51
−0.32]), P < 0.0001], Biological: [r(165) = −0.55 (95% CI: [−0.62
−0.47]), P < 0.0001]). Further analyses showed that our trajectory
modelling approach can be extended to predict data with less than 3
years of clinical diagnosis (Supplementary Figure S5) and future rate of
cognitive decline as measured by standard clinical scales (i.e. MMSE;
Supplementary Figure S6), providing evidence for the clinical relevance
of our approach.
Further, we validated the relationship of the GMLVQ-scalar pro-
jection with cognitive decline for individuals with MCI against a new
independent validation data sample (Longitudinal prediction validation
sample). To calculate the scalar projections, we chose the metric tensor
and prototype positions from the cognitive or biological models with
the median test performance across resampling using the Development
Sample II. To generate a baseline PLS derived grey matter score for the
Longitudinal prediction validation sample, we multiplied the voxel
weights matrix determined by PLSr-RFE on the Development sample
(Figure 3a) with grey matter density from baseline structural scans for
the longitudinal prediction validation sample (i.e. data not used for the
PLSr-RFE feature generation). We observed a significant correlation of
the scalar projection with the rate of future ADNI-Mem change for
cognitive data [r(124) = −0.4, (95% CI: [−0.55 −0.25]), P <
0.0001]. This relationship remained significant when we controlled for:
Age; [r(123) = −0.32, (95% CI: [−0.47 −0.14]), P = 0.0003],
Gender; [r(123) = −0.4, (95% CI: [−0.55 −0.22]), P< 0.0001], or
Education; [r(123) = −0.4, (95% CI: [−0.54 −0.23]), P< 0.0001]).
Further, we observed a significant correlation of the scalar projection
with the rate of future ADNI-Mem change for biological data [r
(124) = −0.68, (95% CI: [−0.76 −0.58]), P < 0.0001] (Figure 6).
This relationship remained significant when we controlled for: Age; [r
(123) = −0.57, (95% CI: [−0.67 −0.46]), P< 0.0001], Gender; [r
Fig. 4. Biological Classification Model - Metric Tensor
Metric tensor for the classification model (sMCI vs pMCI) generated using
biological data (PLS derived grey matter score, β-amyloid, APOE 4). The colour
scale indicates the predictive value for each cell in the metric tensor, where
diagonal terms sum to 1. The diagonal terms show strong contribution of β-
amyloid. The positive off diagonals terms indicate a positive interaction be-
tween β-amyloid and APOE 4. The negative off diagonals terms indicate the
negative interaction of the PLS derived grey matter score with both β-amyloid
and APOE 4. See also Figure S1 for examples of GMLVQ and possible inter-
pretations (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.).
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(123) = −0.63, (95% CI: [−0.71 −0.53]), P< 0.0001], Education; [r
(123) = −0.63, (95% CI: [−0.73 −0.53]), P< 0.0001]. This re-
lationship was not significantly different between Development Sample
I vs. Longitudinal prediction validation samples (Fisher's r to Z, Cog-
nitive model: [Z=−0.1, P = 0.92], Biological model: [Z=−1.76,
P = 0.08]). Further, correlations between the scalar projection and the
rate of future memory decline were significantly stronger for biological
compared to cognitive models (Steiger's Z, [Z=−3.86, P<0.0001]).
This difference between models remained significant when we con-
trolled for Age; (Steiger's Z, [Z=−3.33, P = 0.0004]), Gender; (Stei-
ger's Z, [Z=−3.57, P = 0.0002]), or Education; (Steiger's Z,
[Z=−3.57, P = 0.0002]). Taken together these findings suggest that
the biological model explains significantly larger variance in the rate of
future memory decline than the cognitive model.
Finally, we tested whether our trajectory modelling approach de-
livers stronger predictions when including non-invasively measured
biological data to the basic baseline cognitive model. Adding the
baseline PLS derived grey matter feature and APOE 4 status to the
cognitive model showed a substantial increase in the variance in the
rate of future memory change explained by the scalar projection
(Table 2). These results suggest that predicting the rate of future cog-
nitive decline is enhanced by adding non-invasively measured baseline
Fig. 5. Correlating GMLVQ-Scalar projections with rate of memory change:
Correlation of the GMLVQ-scalar projections derived from the a) cognitive
model, b) biological model with the rate of ADNI-Mem change for Development
Sample I. Red dots indicate pMCI individuals, blue dots indicate sMCI in-
dividuals. The central black line is the regression line for the fit of the GMLVQ-
scalar projection to the rate of ADNI-Mem change; the dashed lines represent
the 95% confidence intervals for this regression line. Data used to train the
model (n = 52) were not used to test the relationship between the scalar
projection and rates of future cognitive decline and are not shown here.
Fig. 6. Correlating Scalar projections from Cognitive and Biological Models
with rate of memory change: Out-of-sample Validation
Correlation of scalar projection derived from the a) cognitive model, b) biolo-
gical model with the rate of ADNI-Mem change for the longitudinal validation
data set. Red dots indicate pMCI individuals, blue dots sMCI individuals. The
central black line is the regression line for the fit of the GMLVQ-scalar pro-
jection to the rate of ADNI-Mem change; the dashed lines represent the 95%
confidence intervals for this regression line. Outliers identified by the Robust
Correlation toolbox (cognitive n = 7, Biological n = 8) are not shown for il-
lustrative purposes. Note that this validation sample includes data from 3 β-
amyloid negative pMCI individuals who had a scalar projection of less than 0.25
(i.e. very close to the sMCI prototype). Investigating the relationship of the
scalar projection to future cognitive decline for these individuals showed dis-
sociable cognitive trajectories from most pMCI individuals.
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biological features to baseline cognitive data.
6. Discussion
Despite the importance of early diagnosis of Alzheimer's disease for
clinical practice and treatment, we still lack robust tools for predicting
individual progression to dementia. The multimodal longitudinal
measurements across large-scale samples available in ADNI provide a
testbed for machine learning approaches that generate predictive fea-
tures and discriminate between patient groups (Weiner et al., 2017,
2015). Here, we propose a novel trajectory modelling approach based
on an integrated feature generation and classification methodology that
predicts individual disease trajectories based on continuous measures of
cognitive decline. Our modelling approach is in line with the current
2018 NIA-AA research framework that defines AD as a continuum and
advances the state-of-the-art and clinical validity of machine learning
applications to the prediction of dementia due to AD in the following
main respects.
First, we successfully predict whether individuals will progress from
MCI to dementia due to AD, employing a transparent machine learning
approach (i.e. prototype based classifier with metric learning and linear
decision boundary) trained on informative and interpretable baseline
cognitive data. We show that baseline composite scores related to
memory and executive function (ADNI-Mem, ADNI-EF composite score)
are highly predictive of disease progression. The high cross-validated
classification performance of our model is in line with previous studies
showing that similar neuropsychological data are predictive of MCI
progression to dementia due to AD (Belleville et al., 2017;
Chapman et al., 2011; Pereira et al., 2018; 2017; Silva et al., 2013;
Tabert et al., 2006). Further, we demonstrate a negative interaction
between baseline cognitive (memory, executive function) and affective
scores that separates individuals into different classes, with higher
baseline affective scores potentially reflecting MCI comorbidity. Pre-
vious studies have shown that moderate to severe depressive symptoms
(i.e. GDS> 15) are predictive of MCI conversion to AD
(Defrancesco et al., 2017), while mild depressive symptoms do not in-
crease conversion risk (Chen et al., 2008; Defrancesco et al., 2017).
Here, we show that the interaction between scores that are indicative of
mild depression (i.e. GDS<10) and memory dysfunction discriminates
stable from progressive MCI individuals. Thus, our metric learning
approach on multimodal data (i.e. cognitive and affective measure-
ments) may provide a means of reducing MCI patient misclassification
due to comorbidity (e.g. affective disturbance).
Second, we developed a supervised feature generation method
(PLSr-RFE) that allows us to derive predictive and interpretable bio-
markers based on structural brain imaging data. We demonstrate that
grey matter density in the medial temporal lobe predicts variability in
memory scores (i.e. ADNI-Mem score). In particular, this grey matter
score is shown to be a highly predictive feature for the classification of
sMCI vs. pMCI individuals, consistent with previous studies showing
that grey matter density in the medial temporal lobe (MTL) is asso-
ciated with AD (Davatzikos et al., 2009; Hedden and Gabrieli, 2004;
Mak et al., 2017; Matsuda, 2016; Rathore et al., 2017) and ADNI-Mem
scores (Nho et al., 2012). Previous work using a similar PLS metho-
dology (sparse PLS) showed a similar spatial pattern of grey matter
voxels that are predictive of MMSE scores (Monteiro et al., 2016). Ex-
tending beyond this work, we generate a biomarker based on a pro-
jection (PLS-derived grey matter score) that is shown to explain more
variance in ADNI-Mem scores than the grey matter density estimated
from the corresponding atlas-defined MTL region. Importantly, we
show that this PLS-derived biomarker predicts cortical tau pathology as
measured by PET, providing a strong link between regional brain
atrophy, memory decline, and tau pathology (Maass et al., 2018). Thus,
our PLSr-RFE methodology has the potential to enhance interoper-
ability across cohorts that typically include grey matter measurements
(i.e. structural MRI scans) but may vary in the inclusion of other vari-
ables (e.g. cognitive or tau measurements). Here, we focused on grey
matter density (un-modulated data), as it has been suggested to reflect
mesoscopic grey matter thinning (Radua et al., 2014) that is evident in
AD (Jagust, 2018). The same PLSr-RFE methodology can be extended to
a wider range of measures derived from structural MRI scans (e.g.
variation in cortical volume, shape and texture) that have been shown
to be predictive of AD (for reviews: (Leandrou et al., 2018; Mateos-
Pérez et al., 2018; Matsuda, 2016)).
Third, our trajectory modelling approach (GMLVQ-Scalar
Projection) extends beyond binary patient classification approaches
(Rathore et al., 2017) that are poorly constrained. Recent methodolo-
gical frameworks for mining neuroimaging data (Jollans et al., 2019)
and predicting progression to AD (Samper-González et al., 2018) have
focused on binary classifications that are based on discrete clinical la-
bels (i.e. stable vs. progressive MCI), as determined by arbitrary criteria
(e.g. within a 3 year period of clinical assessment). As a result, these
approaches are limited by risk of patient misclassification. That is,
patients at the class boundary with different disease trajectories may be
classed in the same MCI group (e.g. a patient who progresses to AD
within 1 day from clinical assessment and a patient who converts in 3
years will be classified as pMCI). Similarly, patients with similar disease
trajectories may be classified in different MCI groups (e.g. a patient who
converts in 3 years will be classified as pMCI, while a patient who re-
mains stable for 3 years and progresses to dementia 1 day after the
clinical assessment will be classified as sMCI). To overcome this lim-
itation and make meaningful predictions in AD, modelling approaches
need to capture continuous information in prognostic trajectories and
consider target uncertainty (i.e. the future clinical diagnosis) (for re-
view (Janssen et al., 2018)). Although recent time-to-event models (e.g.
survival analysis models predicting time to conversion) (Alsaedi et al.,
2018; Casanova et al., 2013; Desikan et al., 2010; Jack et al., 2010;
Landau et al., 2010; Liu et al., 2017; Michaud et al., 2017; Oulhaj et al.,
2009; Young et al., 2014) capture continuous information in patient
trajectories they are limited by target uncertainty; that is, estimating
the exact time to conversion is limited by the frequency of clinical
follow-ups and poor inter-rater reliability (i.e. diagnoses may differ
across clinicians).
Our trajectory modelling approach predicts future ADNI-Mem
scores based on baseline data, allowing us to capture individual disease
trajectories and reducing the risk of patient misclassification. In parti-
cular, we derive continuous prognostic scores of individual cognitive
decline (i.e. scalar projection) by training the model based on ‘noisy’
diagnostic labels (i.e. patient classes that are poorly defined e.g. sMCI vs
pMCI). As our metric learning model has limited freedom (linear low-
Table 2
Correlations of scalar projections with the rate of ADNI-Mem change for models based on cognitive and / or biological data. Pearson's correlation coefficients are
shown for Development Sample (b) based on cross-validation and the independent data used for out of sample validation (longitudinal validation sample).
Data type Pearson's r [95% C.I] Cross validation Pearson's r out-of-sample validation
Biological: (GM+APOE4+ β-Amyloid) −0.55 [−0.66 −0.53] −0.68 [−0.76 −0.58]
Cognitive: (GDS+ADNI-Mem+ADNI-EF) −0.41 [−0.5 −0.30] −0.4 [−0.55 −0.25]
Cognitive+GM −0.46 [−0.52 −0.34] −0.49 [−0.61 −0.35]
Cognitive+APOE 4 −0.47 [−0.55 −0.38] −0.48 [−0.61 −0.33]
Cognitive+GM+APOE 4 −0.5 [−0.57 −0.42] −0.53 [−0.64 −0.4]
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parameter model), separating continuous target values (i.e. in-
dividualised cognitive trajectories) into two broad classes (sMCI vs.
pMCI) forces the model to extract key underlying structures in the data
that distinguish between target values, ignoring subtle differences in
target values. Further, employing separate feature generation (i.e. PLSr-
RFE) and classification (GMLVQ scalar projection) stages allows us to
interrogate interpretable predictive features of progression to AD and
derive predictions that generalise to patient data from independent
samples from the model development sample. This is in contrast to deep
learning methods that require large training samples and are shown to
be difficult to interpret and generalise (Davatzikos, 2019), raising
questions about the clinical utility of these approaches (for review
(Topol, 2019)).
Comparing our trajectory modelling methodology to binary classi-
fications on the same data (i.e. cognitive vs. biological) shows dissoci-
able results. A binary metric learning algorithm shows similar perfor-
mance in the binary classification of MCI subgroups (sMCI vs. pMCI)
when trained on baseline cognitive vs. biological data. In contrast, the
scalar projection derived from biological data explains significantly
higher individual variability in the rate of future cognitive decline than
the scalar projection derived from cognitive data. Further, we demon-
strate that the predictive power of our trajectory modelling metho-
dology is enhanced when including non-invasively measured baseline
biological data in addition to baseline cognitive data. Although our
model shows high accuracy of cognitive decline when trained on cog-
nitive data, there is a substantial gain in predictive efficacy when
adding baseline data on APOE 4 status or grey matter density (PLS
derived grey mater scores). This is consistent with previous studies
(Dukart et al., 2015; Thung et al., 2018; Vogel et al., 2018) showing
enhanced prediction of time to AD conversion when including biolo-
gical compared to neuropsychological data alone.
Previous work on trajectory modelling has focused on discretising
continuous values (i.e. future change in cognitive scores) into latent
classes that are then used as outcome measures in classification models
(Bhagwat et al., 2018; Hochstetler et al., 2015; Wang et al., 2019;
Wilkosz et al., 2010). For example, previous studies (Bhagwat et al.,
2018) used machine learning (i.e. longitudinal Siamese neural-net-
work) to fuse baseline and follow up imaging and clinical scores to
predict whether individuals will decline fast or slow (based on MMSE
scores) or fast, moderate or slow (based on ADAS-cog). Further studies
(Hochstetler et al., 2015) used classification and regression trees on
baseline demographic, lifestyle, cognitive and biological data to classify
individuals in three latent classes (fast, medium or slow decline) with
similar growth patterns of cognitive and functional changes, while
others (Wilkosz et al., 2010) used latent class trajectory models to de-
rive six different trajectories for cognitive and behavioural decline due
to AD. However, the generalisability and interoperability of these ap-
proaches have been recently questioned (Wang et al., 2019). Our tra-
jectory modelling approach differs from this previous work, as it avoids
assumptions related to discretising continuous values. In particular, we
derive a continuous metric (i.e. scalar projection) from a discrete
classification model (i.e. metric learning) that predicts individual rates
of future cognitive change (i.e. change in ADNI-Mem). Finally, our
approach is in line with previous work predicting exact changes in
MMSE or ADAS-Cog scores (Fan et al., 2008; Zhang et al., 2012). In
particular, previous studies used baseline and follow-up structural MRI
and FDG-PET data to predict future scores on cognitive tests at different
time intervals (Zhang et al., 2012), or structural MRI to predict the rate
of change in MMSE scores (Fan et al., 2008). Our modelling approach
differs from this previous work in fusing baseline multimodal data into
a single metric (i.e. scalar projection) to predict future rates of cognitive
change (i.e. change in ADNI-Mem, or MMSE scores).
In sum, we propose a robust methodology based on modelling
multimodal data that determines predictive and interpretable markers
of individual variability in progression to dementia due to AD.
Although our investigations have focused on amnestic MCI, our
methodology has the potential to be extended to predict individual
disease trajectories specific to AD subtypes, following recent work
modelling neuroimaging data (Dong et al., 2016; Young et al., 2018).
Further, previous work on preclinical populations has investigated the
role of grey matter atrophy and cortical amyloid burden in future
cognitive decline (Bilgel et al., 2018; Burnham et al., 2016;
Dumurgier et al., 2017; Insel et al., 2015). Extending our trajectory
modelling approach to preclinical populations using multimodal data
has high clinical relevance, especially as clinical trials are moving to-
wards less severely affected individuals who are unlikely to progress
over the short time scales of clinical trials (Bilgel et al., 2017, 2014;
Grober et al., 2008; Mormino et al., 2014). Thus, our approach has
strong potential to deliver tools of high clinical relevance that reduce
patient misclassification and facilitate effective stratification of in-
dividuals to prognostic or treatment pathways and clinical trials based
on individualised rates of cognitive decline.
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